GlassScriptPhysician profile
David C Heusinkveld
NPI 1962499582
$23,695.82
in general payments reported to CMS, 2019-2025
69 companies · $2,919 in 2025
The $2,919 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,926 · 2020: $3,294 · 2021: $3,492 · 2022: $3,512 · 2023: $3,391 · 2024: $3,162 · 2025: $2,919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,471.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $4,447.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,718.18 | 2019-2025 | |
| Lilly USA, LLC | $1,577.69 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,460.57 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $1,394.73 | 2019-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $999.57 | 2020-2025 | |
| Kowa Pharmaceuticals America, INC. | $946.49 | 2019-2024 | Livalo, Seglentis |
| Glaxosmithkline, LLC. | $848.97 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $763.40 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $738.88 | 2019-2025 | Farxiga, Lokelma, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $699.37 | 2019-2025 | Jardiance, Ofev, Tradjenta |
| Otsuka America Pharmaceutical, INC. | $679.19 | 2021-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $655.80 | 2019-2023 | Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $511.58 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $484.57 | 2019-2024 | Xarelto |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Heusinkveld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.